Moreover, systems-level network analysis identifies critical regulatory nodes, particularly activation of the FOXO1–FOXO3a axis, presenting actionable targets for precision medicine strategies in NSCLC patients. This evidence concerns the gene FOXO3 and non-small cell lung carcinoma.